Marex Group’s GT Biopharma GTBP Stock Holding History

Marex Group’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,000	Closed	-$7.65K	–	583
2023 Q4	$7.65K	Buy	+1,000	New	+$7.31K	﹤0.01%	550

Other funds holding GTBP

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Marex Group's GTBP Position: Q1 2024 in Review

Marex Group sold out of GT Biopharma (GTBP) in Q1 2024, closing a stake of 1,000 shares — an estimated $7.65K sold.

Marex Group first reported a position in GTBP in Q4 2023 and held it in 1 quarter. The position peaked at $7.65K in Q4 2023. 17 funds tracked by Wall St. Rank hold GTBP as of Q1 2024.

Marex Group reported no remaining GT Biopharma position as of Q1 2024 after selling out during the quarter.
Marex Group sold 1,000 GT Biopharma shares in Q1 2024, an estimated $7.65K.
Marex Group first reported a position in GT Biopharma in Q4 2023 and held it in 1 quarter.
Marex Group's GT Biopharma position peaked at $7.65K in Q4 2023.
17 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2024.

Based on Marex Group's 13F filing for Q1 2024, filed 2 Apr 2026.